SCHEMBL10163267

SCHEMBL10163267

COC(=O)c1ccc(Oc2ccc(N)cc2)cn1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.54
PARP10 Q53GL7 1/20 0.45
KDM4E B2RXH2 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
P2RX3 P56373 6/20 0.43
TEAD4 Q15561 1/20 0.42
CDK8 P49336 2/20 0.41
DYRK1A Q13627 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12719462 0.86 MAPK1 (0.56) MAPK1KDM4EL3MBTL1ALDH1A1TDP1
SCHEMBL753224 0.84 MAPK1 (0.54) MAPK1KDM4EL3MBTL1P2RX3CDK8
SCHEMBL24512735 0.84 P2RX3 (0.56) MAPK1KDM4EL3MBTL1P2RX3CDK8
SCHEMBL2416805 0.84 ALDH1A1 (0.42) MAPK1PARP10KDM4EALDH1A1TDP1
SCHEMBL31359497 0.83 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL721291 0.83 MAPK1 (0.65) MAPK1KDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL2417239 0.82 P4HTM (0.51) MAPK1PARP10KDM4EL3MBTL1ALDH1A1
Hydrochloric Acid SCHEMBL14125808 0.82 MAPK1 (0.62) MAPK1KDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL22529696 0.81 MAPK1 (0.54) MAPK1KDM4EL3MBTL1ALDH1A1P2RX3
SCHEMBL30827080 0.81 MAPK1 (0.54) MAPK1KDM4EL3MBTL1ALDH1A1P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2014-11-06 US disclosed
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHCARE LLC (US) 2014-11-06 US disclosed
US-8841330-B2 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2014-09-23 US disclosed
US-8841330-B2 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2014-09-23 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BAYER HEALTHERCARE LLC (US) 2012-06-07 US disclosed
EP-2298311-B1 w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors BAYER HEALTHCARE LLC (US) 2012-05-09 EP disclosed
US-8124630-B2 ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER HEALTHCARE LLC (US) 2012-02-28 US disclosed
US-20120040986-A1 OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS RIEDL BERND (DE) 2012-02-16 US disclosed
US-20120040986-A1 OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS RIEDL BERND (DE) 2012-02-16 US disclosed
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BAYER HEALTHCARE LLC 2008-05-08 US disclosed
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BAYER HEALTHCARE LLC 2008-05-08 US disclosed
US-7351834-B1 ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2008-04-01 US disclosed
US-7351834-B1 ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2008-04-01 US disclosed
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BAYER HEALTHCARE LLC 2008-02-07 US disclosed
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BAYER HEALTHCARE LLC 2008-02-07 US disclosed
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors BAYER HEALTHCARE LLC 2008-01-31 US disclosed
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors BAYER HEALTHCARE LLC 2008-01-31 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed
US-7235576-B1 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors BAYER PHARMACEUTICALS CORPORATION (US) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108672-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors BRAF, RAF1, ARAF MAPK1 564/4885PARP10 2488/4885KDM4E 1426/4885
US-20080032979-A1 Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors BRAF, NRAS, RAF1 MAPK1 2164/4885PARP10 2597/4885KDM4E 765/4885
US-20080027061-A1 omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors MAPK1, MAPK8, MAPK3 MAPK1 1/4885PARP10 3823/4885KDM4E 1916/4885
US-20140329866-A1 OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF MAPK1 286/4885PARP10 2954/4885KDM4E 1407/4885
US-20120040986-A1 OMEGA CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, NRAS, RAF1 MAPK1 671/4885PARP10 2932/4885KDM4E 1477/4885
US-20120142742-A1 OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF MAPK1 564/4885PARP10 2488/4885KDM4E 1426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.